Post CRIS Connect - Advancing CTGTPs in Singapore: Clinical Translation and Clinical Care
Topics
Events
5 June 2026
Discover how Singapore is advancing CTGTPs through ecosystem building, clinical expertise, and manufacturing capabilities, while exploring the future of CAR-T and next-generation cell therapies.
From Breakthrough Science to Bedside: What it takes to Advance CTGTPs in Singapore
As cell, tissue, and gene therapy products (CTGTPs) continue to advance the treatment of complex diseases and offer renewed hope to patients, an important question remains:
What does it take to translate these innovations into real-world patient care?
Last week’s CRIS Connect webinar - attended by around 230 participants, explored how CTGTPs are shaping the future of care in Singapore, with insights from leaders at ACTRIS.
Key takeaways include:
From global innovation to national capability
Adj A/Prof Eng Soo Yap (opens in new tab) described cell and gene therapies as “living drugs” because of their potential to deliver long-term, transformative outcomes. As global innovation accelerates, Singapore is positioning itself as a regional hub, supported by strong clinical expertise, a comprehensive regulatory framework, growing manufacturing capabilities, and coordinated national-level R&D efforts. ACTRIS plays a critical role in enabling this ecosystem by bridging research, clinical translation, and GMP manufacturing, and by building the operational scale needed to make cell therapy products more accessible to patients.Clinical realities of CAR-T therapy
Dr Esther Chan (opens in new tab) highlighted the importance of getting the fundamentals right – from patient selection and disease control to managing complex toxicities such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Beyond innovation, the safe delivery of CAR-T therapies requires structured workflows, multidisciplinary care, and early intervention strategies.Looking ahead
Moderated by A/Prof Aloysius Ho (opens in new tab), the discussion explored emerging frontiers, including the application of CAR-T therapy in solid tumours, in vivo approaches, and applications beyond oncology, pointing to the next wave of innovation.
As Singapore continues to strengthen its CTGTP ecosystem, collaboration across research, clinical care, and manufacturing will be key to translating innovation into meaningful patient outcomes.
